- 9,090$10.2B
1
- 25,200$26.3B
2
- 25,000$10.6B
3
- 14,400$27.5B
4
- 11,851$12.2B
5
- 32,200$47B
6
Genentech - Business Information
Business Services · California, United States · 13,500 Employees
Founded more than 30 years ago, Genentech (gene.com) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.Read More
View Company Info for Free
Who is Genentech
Headquarters
Phone Number
Website
Revenue
Industry
Top Competitors of Genentech
Compare CEO
How does Alexander Hardy compare against Competing Companies' CEOs?

Chief Executive Officer at Genentech
CEO effectiveness to drive business results
VS.

Rob Davis
CEO at Merck
CEO effectiveness to drive business results

Rob Davis
CEO at Merck

Albert Bourla
CEO at Pfizer

Karen S. Lynch
CEO at CVS Health
Genentech Org Chart
Genentech Email Formats
Genentech uses at least 5 email formats with last.first (ex. Smith.John@gene.com) being used 64.4% of the time
Genentech Email Formats | Percentage | |
---|---|---|
last.first | Smith.John@gene.com | 64.4% |
last + first initials | SmithJ@gene.com | 7.9% |
first.last | John.Smith@gene.com | |
first + last | JohnSmith@gene.com | |
first_last | John_Smith@gene.com |
Get Verified Emails
Genentech Company Metrics
$100M
Total Funding Amount
$100M
Most Recent Funding Amount
1
Number of Funding Rounds
Jul 18, 2022
TissueInformatics
Jul 18, 2022
GenMark Diagnostics
Apr 10, 2021
Ventana Medical Systems
May 21, 2018
OncoCloud
Dec 06, 2016
Jecure Therapeutics
Sep 26, 2016
Good Therapeutics
See More Acquisitions & Subsidiaries
Genentech Tech Stack
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Genentech News & Media
Chronic Obstructive Pulmonary Disease Market to Witness Upsurge in Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Companies - Genentech, GlaxoSmithKline, Regeneron, Sanofi, AstraZeneca, Mereo, Inmunotek
The dynamics of the chronic obstructive pulmonary disease market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies. The dynamics of the chronic obstructive pulmonary disease market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremenPeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates
KAWASAKI, Japan--(BUSINESS WIRE)--Combining the PeptiDream's expertise in the field of peptide-RI conjugates, with Genentech's powerful development and commercialization capabilities.Acute Respiratory Distress Syndrome Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Leading Companies to Watch Out - MediciNova, Mesoblast, Veru, Pluristem, Avalo, Boehringer Ingelheim, Genentech, Windtree
The acute respiratory distress syndrome market size shall grow during the forecast period (2023–2032) owing to the launch of upcoming therapies and is expected to increase at a significant rate during the study period. In the year 2021, the US contributed approximately USD 772.3 million (65.8%) to the total ARDS market size in the 7MM. The acute respiratory distress syndrome market size shall grow during the forecast period (2023–2032) owing to the launch of upcomingFDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The acceptance was based on results from the pivotal Phase III COMMODORE 2 study, which demonstrated that in pe
Frequently Asked Questions regarding Genentech
Founded more than 30 years ago, Genentech (gene.com) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.... Read More